<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635098</url>
  </required_header>
  <id_info>
    <org_study_id>DOCTOR-super LuoMa</org_study_id>
    <nct_id>NCT04635098</nct_id>
  </id_info>
  <brief_title>DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR)</brief_title>
  <acronym>DOCTOR</acronym>
  <official_title>The Effect of Dexmedetomidine on Patients With Chronic Insomnia and Its Influence on Circadian Rhythm:Randomized Clinical Trial, Double Blind</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been reported that dexmedetomidine, alpha-2 adrenoceptor agonist, can activate&#xD;
      endogenous neural sleep pathways in the central nervous system. This randomised,&#xD;
      double-blinded and controlled trial was designed to investigate whether dexmedetomidine can&#xD;
      improve/treat chronic insomnia patients. Its effects on sleep quality and improvement, EEG&#xD;
      and circadian rhythm, brain connectivity, cognition and biomarker changes are determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia is a common sleep disorder characterized by difficulty in starting or maintaining&#xD;
      sleep, or poor sleep quality and shortened sleep time. The prevalence of insomnia is about&#xD;
      10-20% of population worldwide; Of which about approximately 50% are chronic. Insomnia is a&#xD;
      risk factor for cognitive impairment and mental disorder development, and other diseases.&#xD;
      Non-pharmacological interventions, e.g. physio-therapy, are often ineffective.&#xD;
      Benzodiazepines and their derivatives are commonly prescribed for those patients but their&#xD;
      side effects and long-time residual sleepy actions are very risky.&#xD;
&#xD;
      Dexmedetomidine is a highly selective α2 adrenergic receptor agonist with sedative, analgesic&#xD;
      and anti-anxiety effects together with remarkable cytoprotective effects. It is widely used&#xD;
      as a sedative. Dexmedetomidine was reported promote sleep. It can also modulate &quot;clock&quot;&#xD;
      protein expression and hence afford a regulatory effects on the circadian rhythm. This&#xD;
      randomised, double-blinded and controlled trial was designed to investigate whether&#xD;
      dexmedetomidine can treat chronic insomnia patients. Its effects on sleep quality and&#xD;
      improvement, EEG and circadian rhythm, brain connectivity, cognition and biomarker changes&#xD;
      are determined. All participants are randomly assigned to receive either dexmedetomidine (a&#xD;
      0.5μg/kg bolus injection for 10 minutes followed by 0.1µg/kg/hr) or placebo (normal saline&#xD;
      infusion with an identical protocol as Dex) for 8 hrs from 10pm to 6 am.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>Eight hours from day 0 22:00 to day 1 06:00</time_frame>
    <description>measured by Sleep monitor , Effective sleep time (the sum of non-rapid Eye movement sleep and rapid eye movement sleep time) as a percentage of the monitoring time. Monitoring time is eight hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMAL1</measure>
    <time_frame>Day 0，Day 1</time_frame>
    <description>sleep protein , Collected from blood lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain functional connectivity</measure>
    <time_frame>Eight hours from day 0 22:00 to day 1 06:00</time_frame>
    <description>According to the collected scalp EEG frequency domain and time domain data, the coherence method is used to measure the phase synchronization degree of different brain regions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>Day0, Day3, Day7</time_frame>
    <description>measured by Scale scores（Mini-mental State Examination），Score from 0 to 30 points, the higher the score, the better the cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6(IL-6)</measure>
    <time_frame>Day 0，Day 1</time_frame>
    <description>cytokines，Collected from blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor(BDNF)</measure>
    <time_frame>Day 0，Day 1</time_frame>
    <description>Collected from blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N2 sleep time percentage</measure>
    <time_frame>Eight hours from day 0 22:00 to day 1 06:00</time_frame>
    <description>measured by Sleep monitor，N2 sleep time as a percentage of total monitoring time. Monitoring time is eight hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep brain functional connectivity</measure>
    <time_frame>Day 0 before 22:00 , Day 3</time_frame>
    <description>we will analysis the brain connection network according to the functional magnetic resonance imaging nonlinear Granger predictive analysis (Granger causality analysis, GCA) method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Chronic Insomnia</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 22:00 pm to 6:00 am</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the same rate as dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>All participants will be randomly assigned to receive either dexmedetomidine or saline</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>dexmedetomidine group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>All participants will be randomly assigned to receive either dexmedetomidine or saline</description>
    <arm_group_label>saline</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 30- 65 years old&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 35 kg/m^2；&#xD;
&#xD;
          -  Clinical diagnosis of chronic insomnia；&#xD;
&#xD;
          -  Must be able to communicate with site personnel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of mental disorders;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Current use of psychotropic drug ;&#xD;
&#xD;
          -  Clinical diagnosis of neurological diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Luo, MD, PhD</last_name>
    <phone>64370045</phone>
    <phone_ext>666225</phone_ext>
    <email>18917762576@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DaQing Ma, MD, PhD</last_name>
    <email>d.ma@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Luo, MD, PhD</last_name>
      <phone>64370045</phone>
      <phone_ext>666225</phone_ext>
      <email>18917762576@163.com</email>
    </contact>
    <contact_backup>
      <last_name>DaQing Ma, MD, PhD</last_name>
      <email>d.ma@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>MiaoYun Xia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu XH, Cui F, Zhang C, Meng ZT, Wang DX, Ma J, Wang GF, Zhu SN, Ma D. Low-dose Dexmedetomidine Improves Sleep Quality Pattern in Elderly Patients after Noncardiac Surgery in the Intensive Care Unit: A Pilot Randomized Controlled Trial. Anesthesiology. 2016 Nov;125(5):979-991.</citation>
    <PMID>27571256</PMID>
  </reference>
  <reference>
    <citation>Akeju O, Hobbs LE, Gao L, Burns SM, Pavone KJ, Plummer GS, Walsh EC, Houle TT, Kim SE, Bianchi MT, Ellenbogen JM, Brown EN. Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study. Clin Neurophysiol. 2018 Jan;129(1):69-78. doi: 10.1016/j.clinph.2017.10.005. Epub 2017 Oct 20.</citation>
    <PMID>29154132</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic insomnia</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Circadian Rhythm</keyword>
  <keyword>Sleep monitoring</keyword>
  <keyword>Brain functional connectivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

